Monday, 28 May 2018


Datesort ascending Type Title Save
18 Jul 2017 Social 320 pt Rheum-Derm clinic in Vancouver - lupus is most common rheum dx; dermatitis & psoriasis most common Derm Dx
17 Jul 2017 News FDA Approves Tremfya (guselkumab) for Plaque Psoriasis
14 Jul 2017 News Statins Improve Survival in Ankylosing Spondylitis
10 Jul 2017 News Orencia Approved for Use in Psoriatic Arthritis
23 Jun 2017 News IV Golimumab in Psoriatic Arthritis
21 Jun 2017 News Tildrakizumab, an IL-23 Inhibitor, is Successful in Plaque Psoriasis
01 Jun 2017 Social 33 pts w/ Axial Spondyloarthritis Rx w/ NSAIDs decreased their MRI sacroiliitis and BM edema w/ longterm NSAIDs only
26 May 2017 Social AS, PsA and uSpA are at increased risk for Acute CV events & stroke events
25 May 2017 News Low Dose Treatment in Ankylosing Spondylitis Still Effective
25 May 2017 News Ixekizumab Effective in TNF Failure Psoriatic Arthritis - SPIRIT-P2 Trial
25 May 2017 Social β-Defensin2 is a biomarker reflects IL-17A-driven skin dz in psoriasis, not PsA. Highly correlates w/ PASI & IL-17A
25 May 2017 Social Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses
24 May 2017 Social European CHMP Recommends Brodalumab (Kyntheum) for use in Plaque Psoriasis. EMA decision awaited.
18 May 2017 Social Hidradenitis suppurativa is uncommon, not rare, prevalence 98/100K, higher in women, age 30-39yr, blacks or biracial
15 May 2017 Social British Society for Rheum 2017 mtg reports smoking is associated w/ more severe AS; data from BSRBR registry for AS
12 May 2017 Social Prevalence of PsA increasing (7.3 in 1997 to 27.3/100k PY 2010), higher in women, w/ increasing DMARD, biologic use
11 May 2017 News Adalimumab Effective in Pediatric Plaque Psoriasis
09 May 2017 News Above-Label Dosing and Noncompliance with Biologics in Psoriatic Arthritis
07 May 2017 Social Pfizer submitted tofacitinib NDA to FDA for psoriatic arthritis. FDA prev denied the NDA for psoriasis w/ CR letter.
02 May 2017 Social 99FM pts had MRI sacroiliitis 8% & met AxSpA criteria 10%. But no control group comparison? Can AS masquerade as FM?